Compare
Tonix Pharmaceuticals Holding Corp. vs Evommune, Inc. vs Emmaus Life Sciences, Inc. vs Pyxis Oncology, Inc.
| Latest fiscal year | Tonix Pharmaceuticals Holding Corp. TNXP | Evommune, Inc. EVMN | Emmaus Life Sciences, Inc. EMMA | Pyxis Oncology, Inc. PYXS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $13.11M | $13.00M | $12.45M | $13.86M |
| Revenue growth (YoY) | +29.8% | +85.7% | -25.2% | -14.2% |
| Gross margin | 49.3% (computed) | n/a | 93.1% | 82.8% (computed) |
| Operating margin | -959.1% | -623.6% | 1.9% | -609.2% |
| Net margin | -946.2% | -529.8% | -60.2% | -574.5% |
| Net income | -$124.02M | -$68.87M | -$7.49M | -$79.62M |
| EPS (Diluted) | -$14.57 | -$11.22 | -$0.12 | -$1.28 |
| Operating cash flow | -$99.84M | -$76.44M | -$11.0K | -$63.50M |
| Free cash flow | -$103.21M | -$76.68M | -$12.0K | -$63.51M |
| Cash & equivalents | $207.64M | $44.06M | $2.13M | $15.42M |
| Total assets | $277.17M | $224.95M | $21.44M | $91.52M |
| Total liabilities | $32.02M | $19.38M | $85.04M | $38.11M |
| Shareholders' equity | $245.15M | $205.57M | -$63.61M | $53.41M |
| Return on year-end equity | -50.6% | -33.5% | n/a | -149.1% |
| Shares outstanding | 12.79M | 31.52M | 70.19M | 62.69M |
Revenue, most recent five fiscal years
| Fiscal year | Tonix Pharmaceuticals Holding Corp. | Evommune, Inc. | Emmaus Life Sciences, Inc. | Pyxis Oncology, Inc. |
|---|---|---|---|---|
| Latest | $13.11M Ended 2025-12-31 | $13.00M Ended 2025-12-31 | $12.45M Ended 2025-12-31 | $13.86M Ended 2025-12-31 |
| 1 year earlier | $10.09M Ended 2024-12-31 | $7.00M Ended 2024-12-31 | $16.65M Ended 2024-12-31 | $16.15M Ended 2024-12-31 |
| 2 years earlier | $7.77M Ended 2023-12-31 | n/a | $29.60M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $18.39M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $20.61M Ended 2021-12-31 | n/a |